

Review Article

Three-Dimensional Bioprinting Nanotechnologies towards Clinical Application of Stem Cells and Their Secretome in Salivary Gland Regeneration

Joao N. Ferreira,^{1,2} Sasitorn Rungarunlert,³ Ganokon Urkasemsin,³
Christabella Adine,¹ and Glauco R. Souza^{4,5}

¹Department of Oral & Maxillofacial Surgery, Faculty of Dentistry, National University of Singapore, Singapore

²National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA

³Department of Preclinical and Applied Animal Science, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand

⁴The University of Texas Health Science Center at Houston, Houston, TX, USA

⁵Nano3D Biosciences (n3D), Houston, TX, USA

Correspondence should be addressed to Joao N. Ferreira; denjnarf@nus.edu.sg

Received 1 October 2016; Accepted 23 November 2016

Academic Editor: Athina Bakopoulou

Copyright © 2016 Joao N. Ferreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Salivary gland (SG) functional damage and severe dry mouth (or xerostomia) are commonly observed in a wide range of medical conditions from autoimmune to metabolic disorders as well as after radiotherapy to treat specific head and neck cancers. No effective therapy has been developed to completely restore the SG functional damage on the long-term and reverse the poor quality of life of xerostomia patients. Cell- and secretome-based strategies are currently being tested *in vitro* and *in vivo* for the repair and/or regeneration of the damaged SG using (1) epithelial SG stem/progenitor cells from salispheres or explant cultures as well as (2) nonepithelial stem cell types and/or their bioactive secretome. These strategies will be the focus of our review. Herein, innovative 3D bioprinting nanotechnologies for the generation of organotypic cultures and SG organoids/mini-glands will also be discussed. These bioprinting technologies will allow researchers to analyze the secretome components and extracellular matrix production, as well as their biofunctional effects in 3D mini-glands *ex vivo*. Improving our understanding of the SG secretome is critical to develop effective secretome-based therapies towards the regeneration and/or repair of all SG compartments for proper restoration of saliva secretion and flow into the oral cavity.

1. Introduction

Irreversible salivary gland (SG) damage and dry mouth (or xerostomia) are commonly present in a vast range of systemic conditions (e.g., Sjögren's syndrome, uncontrolled diabetes, and thyroid disease), and it is particularly severe after radiotherapy (RT) for head and neck cancers (HNC) [1]. On an annual basis, about 500,000 new cases of HNC develop worldwide for whom xerostomia-induced RT is the main treatment modality. Saliva secretions are essential for digestion, lubrication, oral homeostasis, and protection against a variety of environmental hazards. Hence, xerostomia can cause various life disrupting side effects such as oral infections, pain, and tooth loss. These side effects will

impair daily activities related to taste perception, speech, mastication, and swallowing [2]. Salivary secretion has partial improvements after novel modalities, such as SG sparing or intensity-modulated radiation therapy, are utilized [2–4]. Despite these recent efforts, about 40% of dry mouth cases are still irreversible. When the radiation field (during RT) lays on the SG, radiation damage is elicited on the secretory epithelial cell compartment, blood vessels, and adjacent nerves [5, 6]. Following RT, patients lose the majority of acinar epithelial cells (about 80% of total epithelial cells) with the surviving secretory cells being primarily ductal; consequently, RT will irreversibly impact salivary secretion and cause inflammatory damage and fibrosis on the long-term. This radiation damage further depletes the SG stem/progenitor cell niche

deterring healing and natural gland regeneration [5, 7–9]. Yet, no effective therapy has been devised to treat RT-induced xerostomia, and current treatment strategies are confined to the minimization of SG radiation damage or to the administration of artificial saliva substitutes and stimulators of saliva secretion (e.g., pilocarpine) [2, 5].

Radiation-induced xerostomia can be an irreversible lifelong condition that can significantly affect the quality of life of HNC patients. Thus, novel and effective therapeutical strategies for SG hypofunction are required [10]. Due to the depletion of the self-renewable progenitor/stem cell pool during RT damage, cell-based therapies are essential not only to generate new saliva-secreting tissues [10–13] but also to potentially repair the damaged SG via the production and extracellular release of bioactive secretory proteins by transplanted cells [14–17]. This group of non-membrane-bound secretory proteins has been named the salivary secretome [18]. According to the human secretome atlas, salivary glands produce the most abundant proteins found in the human body [18]. Important cellular differences exist within the three major salivary glands (parotid, submandibular, and sublingual), mostly in the ratio of serous to mucous epithelial acinar cells and potentially in their pool of progenitor/stem cells. Despite these differences, researchers mainly focused their secretome-based and SG regenerative studies with 3D systems on either the submandibular or the parotid glands. The salivary secretome produced by different stem/progenitor cells will be discussed in the next sections since it could transform the way we restore the salivary flow in patients with xerostomia in the near future.

2. Salivary Stem/Progenitor Cells and Their Secretome

The first proof of concept study on transplantation of autologous SG cells to rescue salivary hypofunction using in vitro floating spheroid-like cultures of mouse SG progenitor cells, named salispheres. In vitro salisphere cultures have been shown to enrich SG stem/progenitor cell populations that include KIT (C-KIT, CD117), Sca-1, and Mushashi-1 [11]. KIT-expressing (KIT+) progenitors are also found in other epithelial organs beside the SG, such as the prostate gland and lungs, where KIT+ progenitors have remarkable regeneration capabilities [20, 21]. In a salisphere study in mice, 100–300 KIT+ donor-derived cells isolated from the salisphere cultures were sufficient to form both new acini and saliva-transporting ductal structures, restoring the morphology and function of irradiated SG. Since human salispheres do contain KIT+ cells, there is a potential for future clinical use of KIT+ cell subpopulations [22]. Recently, Pringle and others [13] have successfully transplanted human salispheres into irradiated mice restoring the salivary flow, particularly when these salispheres were positively selected for KIT. However, the subpopulation of KIT+ cells in human SGs is very limited being less than 0.4% of the total population in younger adults, and this number substantially decreases with aging [13]. Moreover, these salispheres have a restricted in vitro self-renewal and proliferative capacities that confines their growth to 2–3 population doublings at earlier passages (P1–P4) [13].

TABLE 1: List of secretome components (matrix peptides, cytokines, growth factors, and enzymes) from SG cell lines that can be potentially used in SG regeneration strategies. More details about each secretome component can be found in [18, 23]. ALDH3: aldehyde dehydrogenase 3; EDA: ectodysplasin A; EGF: epidermal growth factor; FGF: fibroblast growth factor; IGF: insulin growth factor; IL: interleukin; SHH: sonic hedgehog; SCF: stem cell factor.

Secretome components	References
ALDH3 activator	[24]
EDA	[25]
EGF	[26]
FGF2	[27]
FGF7	[28, 29]
FGF10	[29–31]
Heparan sulfate	[31, 32]
IGF1	[33]
IL-6	[34]
SHH	[35]
SCF	[32]
Wnt	[36–38]

Thus, it is crucial to understand how progenitors proliferate and expand particularly during organogenesis. Several researcher groups have demonstrated that KIT and fibroblast growth factor receptor 2b (FGFR2b) signaling are essential for progenitor survival and expansion in the fetal submandibular gland, lung, pancreas, tooth, and skin [39–41]. Moreover, other putative markers can be used to isolate SG stem/progenitor cells including KRT5 (Cytokeratin 5), CD49f, CD29 (Itga1), CD133 (Prom1), Sca1, CD44, CD34, CD90 (Thy1), CD105, CD9, and CD81, but only few populations were proven to actively restore damaged glands [11, 42–45]. Yet, the KIT+ cell population still appears to have the highest stem/progenitor-like potential.

Research efforts have been made to increase the number of KIT+ cells ex vivo using growth factors [32] or to administer secretome factors to reverse SG damage in vivo [60]. Several secretome components have been studied including specific heparan sulfate peptides [32] and several growth factors and cytokines (see Table 1 for a complete list). The majority of these secretome components (EGF, IGF1, FGF2 [26, 27, 33], FGF7 (or KGF) [28], IL-6 [34], ALDH3 [24], or EDA activators [25]) have similar cellular downstream effects such as the reduction in cell apoptosis and/or the promotion of epithelial proliferation. These secretome-based strategies could be advantageous, although the absolute cell number required for functional regeneration of the human SG is still unknown. Instead, non-SG cells may be considered to curb this constraint.

Taken together, multiple research groups have shown that rodent SG-specific epithelial cell transplantation is a feasible approach to repair irradiated SGs. Future studies will determine whether human SG cells behave in a similar manner in ex vivo and in vivo assays [13]. While success has been achieved with epithelial KIT+ cells in rodents,

TABLE 2: In vivo and in vitro tested oral stem cell lines for salivary gland regeneration. SG: salivary gland, BM: bone marrow, MSC: mesenchymal stem cells, ESC: embryonic stem cells, and iPSC: induced-pluripotent stem cells.

Tested cell sources	Origin (species)	References
Major SG progenitor/stem cells	Mouse, rat, human	[46–48]
Minor SG epithelial cells	Human	[49]
BM-derived stem cells	Human	[50, 51]
BM-derived MSC	Human	[14, 52]
Adipose-derived MSC	Human	[53, 54]
Minor SG-derived MSC-like cells	Human	[55]
Amniotic epithelial cells	Human	[56, 57]
ESC	Mouse	[58]
iPSC	Mouse	[59]

currently, other more multipotent stem/progenitor cell candidates and/or compartment reservoir cells can be investigated (e.g., cytokeratin 14) [61]. Despite this, in clinical scenarios where autologous SG cell numbers are reduced, we may need to take advantage of the regenerative capacity of non-SG stem cells, nonepithelial cells (e.g., bone marrow-derived), or simply their secretome. These potential therapeutical options are reviewed in the following section.

3. Nonsalivary Gland Cells and Their Secretome

There are a vast number of reports on the advantageous effects of non-SG stem cells and their secretome to regenerate irradiated SGs (see Tables 2 and 3). These reports include several types of stem cells such as bone marrow- (BM-) derived cells [63, 64], BM-derived mesenchymal stem cells (MSCs) [14, 52], human adipose-derived MSCs [53, 54], SG-derived MSC-like cells [55], amniotic cells [56, 57], embryonic stem cells (ESC) [58], and induced-pluripotent stem cells (iPSC) [59].

Recently, BM-derived transplants using either mesenchymal stem cells (MSC) or BM secretome (also named “soup” or “bioactive lysates”) have been shown to induce paracrine prosurvival effects on remaining SG tissues towards a more functional SG tissue architecture [14, 15]. When intraglandular transplantation of BM cells and their secretome was implemented, the outcomes in irradiated mouse SG were promising; and those included an improvement in saliva production, reduction in apoptosis, and changes in microvessel density [15]. Earlier studies in mouse irradiated SG had similar functional outcomes, when BM-derived cells were mobilized by G-CSF/FLT3/SCF [50, 62]. The clinical translation of these cellular paracrine effects led investigators to identify such bioactive secretome components secreted by BM-derived cells [15, 16]. Protein microarrays detected several angiogenesis-related factors (CD26, FGF1, HGF, MMP-8, MMP-9, OPN, PF4, and SDF-1) and cytokines (IL-1ra, IL-16) in the BM secretome (Table 3) [16]; thereby, several signaling pathways may be involved and the contribution of each secretome component towards epithelial repair and SG regeneration requires further investigation.

TABLE 3: List of secretome components (cytokines, growth factors, and proteinases) from adult stem cells (e.g., bone marrow-derived stem cells and adipose mesenchymal stem cells) that can be potentially used in SG regeneration strategies. More details about each secretome component can be found in [18, 23]. FGF: fibroblast growth factor; FLT3: Fms related tyrosine kinase 3; G-CSF: granulocyte-colony stimulating factor; GM-CSF: granulocyte macrophage-colony stimulating factor; HGF: hepatocyte growth factor; IGF: insulin growth factor; IL: interleukin; MMP: matrix metalloproteinase; OPN: osteopontin; PF4: platelet factor 4; SCF: stem cell factor; SDF1: stromal cell derived factor-1; VEGF: vascular endothelial growth factor.

Secretome components	References
CD26	[16]
FGF1	[16]
FLT-3	[62]
G-CSF	[62]
GM-CSF	[17]
HGF	[16]
IGF-1	[17]
IL-1ra	[16]
IL-6	[17]
IL-16	[16]
MMP8	[16]
MMP9	[16]
OPN	[16]
PF4	[16]
SCF	[62]
SDF1	[16]
VEGF	[17]

Despite tentative differentiation of BM-derived cells and MSCs into SG acinar cells in vitro, their actual contribution to epithelial differentiation in vitro and in vivo is puzzling. Highly homogenous BM clonal MSC (BM-cMSC) has recently shown potential to regenerate SGs, although the current mechanisms of regeneration are not well understood [14]. In addition, an in vitro study using BM stem cells (BMSCs) cocultured with neonatal rat parotid acinar cells

showed an increase in the induction of acinar-specific α -amylase expression in BMSCs [51]. This coculture scenario with mesenchymal and epithelial stem/progenitor cells can be an interesting therapeutical approach when used in combination with relevant secretome factors. Further studies are still needed to test the secretory function of these acinar-like cells from bone marrow sources. As somewhat expected, both BM-MSC and mesenchymal-like cells derived from SG can suppress the immune system [65].

Interestingly, researchers have also looked at adipose sources of stem cells. Human adipose-derived mesenchymal stem cells (hAdMSCs) via systemic administration exhibit improved salivary flow rates 4 months after radiation therapy [54]. Glands with hAdMSC transplants showed lesser epithelial acinar apoptosis and tissue fibrosis and higher secretory mucin and amylase levels. At 4 weeks, a large number of infused hAdMSCs were detected *in vivo* and were found to have differentiated [54]. Moreover, the secretome from hypoxia-preconditioned hAdMSC comprised high levels of GM-CSF, VEGF, IL-6, and IGF-1 (Table 3) [17]. This hAdMSC secretome strongly induced epithelial proliferation and exerted antiapoptotic effects in the SG *in vivo*. A common finding across these adult stem cell secretome studies is the presence of secretome-based paracrine effects to reduce radiation-induced epithelial apoptosis, proliferate the host SG progenitor cells, and induce angiogenesis.

The known components of the secretome derived from adult stem cells are summarized in Table 3 since they are multiple. The antiapoptotic, proliferative, and proangiogenesis cues found in the secretome can support not only the repair of the epithelial cells but also the microenvironment [17]. However, the following question can be posed: could the secretome strategy be a successful therapy in every patient, particularly for the patients without any remaining SG cells left after radiotherapy? The secretome strategy like the current ones involving salivary stimulation (e.g., stimulation with oral pilocarpine tablets) relies on the amount of remaining SG cells; thus, clinical outcomes will depend on the remaining cells that need paracrine stimulation.

While proangiogenesis factors have been reported in certain secretomes, it is not known yet whether neurotrophic factors are present [66]. Parasympathetic neurons are known to support epithelial regeneration after RT [43, 60]. Neurotrophic factors such as neurturin (NRTN) or glial cell-derived neurotrophic factor (GDNF) are currently being tested to revert the hypofunctional status of irradiated SGs [43, 60].

Other pluripotent cell types such as ESC and iPSC have recently been investigated as new cell sources to generate mature salivary gland cells [58, 59]. A study with mouse ESCs cocultured with human SG-derived fibroblast has provided (to ESCs) the cues to express SG-specific markers and to reconstitute SG structures; however, it is still unclear whether SG function can be restored [58]. Both ESC- [58] and iPSC-derived SG cells [59] have the potential to be an adjuvant cell-based therapy as long as properties such as genomic stability and lack of tumorigenesis are secured at transplantation.

Nonetheless, in clinical scenarios where whole new SG organs or mini-glands are necessary for *in vivo* transplantation, three-dimensional (3D) SG *in vitro* culture systems (with or without bioscaffolds) are required to integrate multiple cell lines (under specific growth factor conditions) for the generation of all gland compartments (acinar and ductal epithelial, myoepithelial, endothelial/vascular, and neuronal).

4. Generating Salivary Gland Organoids/Organs and the Role of 3D Bioprinting

A recent breakthrough in the field of SG whole organ regeneration showed that a bioengineered gland made from fetal epithelium and mesenchyme can be transplanted into an adult mouse to form a new whole functional gland in the adult microenvironment [67]. This bioengineered gland contained a variety of embryonic cells, including progenitors of epithelial, mesenchymal, endothelial, and neuronal cells. Importantly, the gland reconnected with the existing ductal system and was functional in terms of saliva secretion, protection of the oral cavity from bacteria, and restoration of normal swallowing. Thus, this concept may lead to the creation of new surgical techniques for the prompt implantation of *ex vivo* SG organs to integrate with the existing circulatory and nervous system structures and align endogenous salivary ductal structures. However, this mouse model system may not fully translate into clinics due to the use of fetal glands. Thus, this major advance prompted researchers to develop 3D organotypic cultures to produce SG organoids or mini-glands that can recapitulate the *in vivo* native environment and SG morphology and architecture [10].

As a result, novel 3D bioprinting nanotechnologies have been recently developed using magnetic patterning or levitation, in which cells bind with a magnetic nanoparticle assembly overnight to render them magnetic [19]. These bioprinting systems are time efficient as they require less than 24 hours of working time to assemble cells in 3D, depending on the cell type and number of magnetic nanoparticles used (Figures 1 and 2(a)) [68, 69]. Their magnetic nanoparticle assembly includes gold, iron oxide, and poly-L-lysine, which can easily tag different cell types at the plasma membrane level. When resuspended in medium, an external magnetic field levitates and can concentrate different SG cells at the air-liquid interface, where they aggregate to form larger 3D organoids (Figures 1 and 2(a)). The resulting dense cultures can synthesize extracellular matrix and can be analyzed similarly to other 2D/3D culture systems, using assays/techniques such as cytotoxicity assays, immunohistochemical analysis, western blotting, and other biochemical assays [70]. These 3D bioprinted systems have been previously found to recapitulate the native extracellular matrix from several tissues such as fat, lung, aortic valve, blood vessels, and breast and glioblastoma tumors [19, 68, 69, 71–74].

These magnetic-based bioprinting strategies are an avenue that we are currently exploring since their biocompatibility is comparable to conventional 3D systems using




FIGURE 1: Diagram showing magnetic 3D bioprinting (M3DB) sphere assembly culture system by magnetic force driven patterning of tagged cells [19].

centrifugation-based force aggregation (Figure 2(b)). These bioprinting cell assembly systems can integrate all human SG cellular compartments (acinar/ductal epithelial, myoepithelial, endothelial, and neuronal) into organotypic cultures. More interestingly, these 3D bioprinting systems have been tested in cultures with oral stem cells such as human dental pulp stem cells (hDPSC) in combination with secretome components (e.g. FGF-10) and have shown to produce α -amylase-secreting cells (Figure 2(c)). However, the polarity in these secretory epithelial cells still needs to be evaluated.

During the development of the SG organoid, the creation of the apicobasal polarity in epithelial cells and of branched lumenized ducts is paramount to achieve a proper directionality for the salivary flow and production of saliva. These epithelial polarity properties of the SG organoids or mini-glands have been difficult to achieve [75]. However, these bioprinting strategies have shown promise when applied in *in vivo* rodent models using magnets [76]. In this particular *in vivo* study, the magnetized stem cells were biocompatible and successfully targeted a locally damaged neuronal tissue restoring its function.

Taken together, these innovative magnetic-based 3D bioprinting strategies are relevant in the SG regeneration field because they may (1) first generate scaled-up xenofree biocompatible 3D tissue compartments that provide an architecture with environmental cues to support cell growth, differentiation, and biointegration in the remaining tissues (after damage) to restore homeostasis and functionality; (2) secondly they may establish coculture methods to generate SG cell-derived secretome, matrices, and tissue compartments on a scaled-up manner. These cocultures will allow researchers to integrate, in a 3D architecture, the complexity of different human SG component; and (3) lastly test new surgical techniques using magnetic fields *in vivo* to promptly

implant and hold/stabilize magnetized SG organoids/mini-glands onto the injury site [76].

5. Future Directions

There has been a research trend towards the development of secretome-based therapeutical strategies to repair and/or restore salivary glands (SG) damaged by radiotherapy. These strategies have been relatively successful in rodent models for the clinical scenarios where the majority of SG cells and tissue compartments still remain. Nonetheless, when a patient needs a whole new SG, organotypic 3D cell culture systems are required to generate robust 3D organoids or mini-glands *ex vivo* for proper acinar epithelial stimulation, saliva production, and release into the oral cavity. These 3D mini-glands can be established using coculture systems to integrate in 3D the complexity of the different SG cellular/tissue components, such as epithelial acinar and ductal cells, myoepithelial cells, the networks of parasympathetic nerves, and lumenized ducts and vessels. For this purpose, novel 3D bioprinting approaches have been developed to assemble all the above SG cells in coculture and produce 3D tissue compartments and ductal structures that resemble mini-SG.

In summary, secretome-based and 3D organotypic cell-based strategies will certainly become the next generation of biomedical therapies to either repair a damaged SG or to develop an *in vitro* SG organoid/mini-gland for transplantation in humans suffering from xerostomia.

Competing Interests

All authors have nothing to disclose and have no financial interests, except for Dr. Glauco Souza. Dr. Glauco Souza is the




FIGURE 2: Morphology and viability of the M3DB spheroid-like organoids after 3D bioprinting of human dental pulp stem cell (hDPSC) cultures in a 96-well plate. (a) Morphology of the M3DB spheroids after 7 h and 32 h of culture of 3×10^5 hDPSC using increased concentration of magnetic nanoparticles for cellular tagging and magnetization. (b) ATP activity of M3DB compared to a conventional 3D system (3D control) from baseline to 72 hours after seeding 1×10^5 hDPSC at baseline (time 0 h). ATP activity was measured by a luciferase ATP-based 3D assay (CellTiter-Glo 3D Cell Viability Assay, Promega, USA) with a Glomax luminometer (RLU: raw luminescent units); significant difference found between the two culture systems (M3DB and 3D control) at 72 h (* $p = 0.0286$); $N = 4-5$; Two-tailed t -test. (c) Organoids expressing α -amylase salivary protein after epithelial differentiation (GlutaMAX basal media with FGF-10 40 ng, Gibco) of hDPSC for 14 days. Organoids were processed for whole mount immunofluorescence staining with α -amylase primary antibody and Alexa Fluor[®] 488 (green) followed by confocal fluorescence microscopy. Images are a maximum intensity projection of a z-stack of images taken through the entire organoid thickness (magnification: 10x; scale bar: 250 μ m).

President (CEO) and Chief Scientific Officer of the company “Nano3D Biosciences Inc.,” Houston, TX, USA; and he is affiliated as an Adjunct Assistant Professor at The University of Texas Health Science Center at Houston, Texas, USA.

Acknowledgments

Our research studies are currently funded by the National University of Singapore ODPRT start up grant (R-221-000-072-133), by the Singapore’s National Medical Research Council grant (CNIG14NOV008), and by Mahidol University.

References

- [1] I. von Bültzingslöwen, T. P. Sollecito, P. C. Fox et al., “Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology*, vol. 103, supplement, pp. S57.e1–S57.e15, 2007.
- [2] O. B. Wijers, P. C. Levendag, M. M. J. Braaksma, M. Boonzaaijer, L. L. Visch, and P. I. M. Schmitz, “Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors,” *Head & Neck*, vol. 24, no. 8, pp. 737–747, 2002.
- [3] S. B. Jensen, A. M. L. Pedersen, A. Vissink et al., “A systematic review of salivary gland hypofunction and xerostomia induced

- by cancer therapies: management strategies and economic impact," *Supportive Care in Cancer*, vol. 18, no. 8, pp. 1061–1079, 2010.
- [4] C. M. Nutting, J. P. Morden, K. J. Harrington et al., "Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial," *The Lancet Oncology*, vol. 12, no. 2, pp. 127–136, 2011.
 - [5] A. Vissink, J. B. Mitchell, B. J. Baum et al., "Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers," *International Journal of Radiation Oncology Biology Physics*, vol. 78, no. 4, pp. 983–991, 2010.
 - [6] O. Grundmann, G. C. Mitchell, and K. H. Limesand, "Sensitivity of salivary glands to radiation: from animal models to therapies," *Journal of Dental Research*, vol. 88, no. 10, pp. 894–903, 2009.
 - [7] B. J. Baum, "Principles of saliva secretion," *Annals of the New York Academy of Sciences*, vol. 694, pp. 17–23, 1993.
 - [8] B. J. Baum, C. Zheng, I. Alevizos et al., "Development of a gene transfer-based treatment for radiation-induced salivary hypofunction," *Oral Oncology*, vol. 46, no. 1, pp. 4–8, 2010.
 - [9] I. M. Lombaert and M. P. Hoffman, "Stem cells in salivary gland development and regeneration," in *Stem Cells in Craniofacial Development and Regeneration*, G.T.-J. Huang and I. Thesleff, Eds., pp. 271–284, John Wiley & Sons, New York, NY, USA, 2013.
 - [10] I. Lombaert, M. M. Movahednia, C. Adine, and J. N. Ferreira, "Salivary gland regeneration: therapeutic approaches from stem cells to tissue organoids," *Stem Cells*, 2016.
 - [11] I. M. A. Lombaert, J. F. Brunsting, P. K. Weirenga et al., "Rescue of salivary gland function after stem cell transplantation in irradiated glands," *PLoS ONE*, vol. 3, no. 4, Article ID e2063, 2008.
 - [12] T. Sugito, H. Kagami, K. Hata, H. Nishiguchi, and M. Ueda, "Transplantation of cultured salivary gland cells into an atrophic salivary gland," *Cell Transplantation*, vol. 13, no. 6, pp. 691–699, 2004.
 - [13] S. Pringle, M. Maimets, M. van der Zwaag et al., "Human salivary gland stem cells functionally restore radiation damaged salivary glands," *Stem Cells*, vol. 34, no. 3, pp. 640–652, 2016.
 - [14] J.-Y. Lim, T. Yi, J.-S. Choi et al., "Intraglandular transplantation of bone marrow-derived clonal mesenchymal stem cells for amelioration of post-irradiation salivary gland damage," *Oral Oncology*, vol. 49, no. 2, pp. 136–143, 2013.
 - [15] S. D. Tran, Y. Liu, D. Xia et al., "Paracrine effects of bone marrow soup restore organ function, regeneration, and repair in salivary glands damaged by irradiation," *PLoS ONE*, vol. 8, no. 4, Article ID e61632, 2013.
 - [16] D. Fang, S. Hu, Y. Liu, V.-H. Quan, J. Seuntjens, and S. D. Tran, "Identification of the active components in Bone Marrow Soup: a mitigator against irradiation-injury to salivary glands," *Scientific Reports*, vol. 5, Article ID 16017, 2015.
 - [17] H.-Y. An, H.-S. Shin, J.-S. Choi, H. J. Kim, J.-Y. Lim, and Y.-M. Kim, "Adipose mesenchymal stem cell secretome modulated in hypoxia for remodeling of radiation-induced salivary gland damage," *PLoS ONE*, vol. 10, no. 11, Article ID e0141862, 2015.
 - [18] M. Uhlén, "Proteomics. Tissue-based map of the human proteome," *Science*, vol. 347, no. 6220, Article ID 1260419, 2015.
 - [19] W. L. Haisler, D. M. Timm, J. A. Gage, H. Tseng, T. C. Killian, and G. R. Souza, "Three-dimensional cell culturing by magnetic levitation," *Nature Protocols*, vol. 8, no. 10, pp. 1940–1949, 2013.
 - [20] K. G. Leong, B.-E. Wang, L. Johnson, and W.-Q. Gao, "Generation of a prostate from a single adult stem cell," *Nature*, vol. 456, no. 7223, pp. 804–810, 2008.
 - [21] J. Kajstura, M. Rota, S. R. Hall et al., "Evidence for human lung stem cells," *The New England Journal of Medicine*, vol. 364, no. 19, pp. 1795–1806, 2011.
 - [22] J. Feng, M. van der Zwaag, M. A. Stokman, R. van Os, and R. P. Coppes, "Isolation and characterization of human salivary gland cells for stem cell transplantation to reduce radiation-induced hyposalivation," *Radiotherapy and Oncology*, vol. 92, no. 3, pp. 466–471, 2009.
 - [23] K. Musselmann, J. A. Green, K. Sone et al., "Salivary gland gene expression atlas identifies a new regulator of branching morphogenesis," *Journal of Dental Research*, vol. 90, no. 9, pp. 1078–1084, 2011.
 - [24] N. Xiao, H. Cao, C.-H. Chen et al., "A novel aldehyde dehydrogenase-3 activator (Alda-89) protects submandibular gland function from irradiation without accelerating tumor growth," *Clinical Cancer Research*, vol. 19, no. 16, pp. 4455–4464, 2013.
 - [25] G. Hill, D. Headon, Z. I. Harris, K. Huttner, and K. H. Limesand, "Pharmacological activation of the EDA/EDAR signaling pathway restores salivary gland function following radiation-induced damage," *PLoS ONE*, vol. 9, no. 11, Article ID 112840, 2014.
 - [26] B. Ohlsson, C. Jansen, I. Ihse, and J. Axelson, "Epidermal growth factor induces cell proliferation in mouse pancreas and salivary glands," *Pancreas*, vol. 14, no. 1, pp. 94–98, 1997.
 - [27] T. Kojima, S.-I. Kanemaru, S. Hirano et al., "The protective efficacy of basic fibroblast growth factor in radiation-induced salivary gland dysfunction in mice," *The Laryngoscope*, vol. 121, no. 9, pp. 1870–1875, 2011.
 - [28] I. M. A. Lombaert, J. F. Brunsting, P. K. Wierenga, H. H. Kampinga, G. De Haan, and R. P. Coppes, "Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of the stem/progenitor pool," *STEM CELLS*, vol. 26, no. 10, pp. 2595–2601, 2008.
 - [29] H. P. Makarenkova, M. P. Hoffman, A. Beenken et al., "Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis," *Science Signaling*, vol. 2, no. 88, p. ra55, 2009.
 - [30] V. N. Patel, S. M. Knox, K. M. Likar et al., "Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis," *Development*, vol. 134, no. 23, pp. 4177–4186, 2007.
 - [31] V. N. Patel, K. M. Likar, S. Zisman-Rozen et al., "Specific heparan sulfate structures modulate FGF10-mediated submandibular gland epithelial morphogenesis and differentiation," *Journal of Biological Chemistry*, vol. 283, no. 14, pp. 9308–9317, 2008.
 - [32] V. N. Patel, I. M. A. Lombaert, S. N. Cowherd et al., "Hs3st3-modified heparan sulfate controls KIT+ progenitor expansion by regulating 3-O-sulfotransferases," *Developmental Cell*, vol. 29, no. 6, pp. 662–673, 2014.
 - [33] K. H. Limesand, S. Said, and S. M. Anderson, "Suppression of radiation-induced salivary gland dysfunction by IGF-1," *PLoS ONE*, vol. 4, no. 3, Article ID e4663, 2009.
 - [34] Y. Marmar, R. Adar, S. Gaska et al., "Radiation-induced loss of salivary gland function is driven by cellular senescence and prevented by IL-6 modulation," *Cancer Research*, vol. 76, no. 5, pp. 1170–1180, 2016.
 - [35] B. Hai, L. Qin, Z. Yang et al., "Transient activation of hedgehog pathway rescued irradiation-induced hyposalivation by

- preserving salivary stem/progenitor cells and parasympathetic innervation," *Clinical Cancer Research*, vol. 20, no. 1, pp. 140–150, 2014.
- [36] B. Hai, Z. Yang, L. Shangguan, Y. Zhao, A. Boyer, and F. Liu, "Concurrent transient activation of Wnt/ β -catenin pathway prevents radiation damage to salivary glands," *International Journal of Radiation Oncology, Biology, Physics*, vol. 83, no. 1, pp. e109–e116, 2012.
- [37] B. Hai, Z. Yang, S. E. Millar et al., "Wnt/ β -catenin signaling regulates postnatal development and regeneration of the salivary gland," *Stem Cells and Development*, vol. 19, no. 11, pp. 1793–1801, 2010.
- [38] M. Maimets, C. Rocchi, R. Bron et al., "Long-term in vitro expansion of salivary gland stem cells driven by wnt signals," *Stem Cell Reports*, vol. 6, no. 1, pp. 150–162, 2016.
- [39] I. M. A. Lombaert, S. R. Abrams, L. Li et al., "Combined KIT and FGFR2b signaling regulates epithelial progenitor expansion during organogenesis," *Stem Cell Reports*, vol. 1, no. 6, pp. 604–619, 2013.
- [40] A. Petiot, F. J. A. Conti, R. Grose, J.-M. Revest, K. M. Hodivala-Dilke, and C. Dickson, "A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning," *Development*, vol. 130, no. 22, pp. 5493–5501, 2003.
- [41] L. De Moerlooze, B. Spencer-Dene, J.-M. Revest, M. Hajhosseini, I. Rosewell, and C. Dickson, "An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis," *Development*, vol. 127, no. 3, pp. 483–492, 2000.
- [42] L. S. Y. Nanduri, M. Maimets, S. A. Pringle, M. Van Der Zwaag, R. P. Van Os, and R. P. Coppes, "Regeneration of irradiated salivary glands with stem cell marker expressing cells," *Radiotherapy and Oncology*, vol. 99, no. 3, pp. 367–372, 2011.
- [43] S. M. Knox, I. M. A. Lombaert, C. L. Haddox et al., "Parasympathetic stimulation improves epithelial organ regeneration," *Nature Communications*, vol. 4, article 1494, 2013.
- [44] S. Pradhan-Bhatt, D. A. Harrington, R. L. Duncan, M. C. Farach-Carson, X. Jia, and R. L. Witt, "A novel in vivo model for evaluating functional restoration of a tissue-engineered salivary gland," *Laryngoscope*, vol. 124, no. 2, pp. 456–461, 2014.
- [45] N. Rotter, J. Oder, P. Schlenke et al., "Isolation and characterization of adult stem cells from human salivary glands," *Stem Cells and Development*, vol. 17, no. 3, pp. 509–518, 2008.
- [46] J. Jeong, H. Baek, Y.-J. Kim et al., "Human salivary gland stem cells ameliorate hyposalivation of radiation-damaged rat salivary glands," *Experimental and Molecular Medicine*, vol. 45, no. 11, article no. e58, 2013.
- [47] R. P. Coppes and M. A. Stokman, "Stem cells and the repair of radiation-induced salivary gland damage," *Oral Diseases*, vol. 17, no. 2, pp. 143–153, 2011.
- [48] L. S. Y. Nanduri, I. M. A. Lombaert, M. Van Der Zwaag et al., "Salisphere derived c-Kit⁺ cell transplantation restores tissue homeostasis in irradiated salivary gland," *Radiotherapy and Oncology*, vol. 108, no. 3, pp. 458–463, 2013.
- [49] S. I. Jang, H. L. Ong, A. Gallo, X. Liu, G. Illei, and I. Alevizos, "Establishment of functional acinar-like cultures from human salivary glands," *Journal of Dental Research*, vol. 94, no. 2, pp. 304–311, 2015.
- [50] I. M. A. Lombaert, P. K. Wierenga, T. Kok, H. H. Kampinga, G. DeHaan, and R. P. Coppes, "Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands," *Clinical Cancer Research*, vol. 12, no. 6, pp. 1804–1812, 2006.
- [51] C.-Y. Lin, B.-S. Lee, C.-C. Liao, W.-J. Cheng, F.-M. Chang, and M.-H. Chen, "Transdifferentiation of bone marrow stem cells into acinar cells using a double chamber system," *Journal of the Formosan Medical Association*, vol. 106, no. 1, pp. 1–7, 2007.
- [52] J. Xu, D. Wang, D. Liu et al., "Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome," *Blood*, vol. 120, no. 15, pp. 3142–3151, 2012.
- [53] T. Kojima, S.-I. Kanemaru, S. Hirano et al., "Regeneration of radiation damaged salivary glands with adipose-derived stromal cells," *Laryngoscope*, vol. 121, no. 9, pp. 1864–1869, 2011.
- [54] J.-Y. Lim, J. C. Ra, I. S. Shin et al., "Systemic transplantation of human adipose tissue-derived mesenchymal stem cells for the regeneration of irradiation-induced salivary gland damage," *PLoS ONE*, vol. 8, no. 8, Article ID e71167, 2013.
- [55] L. Lu, Y. Li, M.-J. Du et al., "Characterization of a self-renewing and multi-potent cell population isolated from human minor salivary glands," *Scientific Reports*, vol. 5, Article ID 10106, 2015.
- [56] G.-L. Huang, N.-N. Zhang, J.-S. Wang, L. Yao, Y.-J. Zhao, and Y.-Y. Wang, "Transdifferentiation of human amniotic epithelial cells into acinar cells using a double-chamber system," *Cellular Reprogramming*, vol. 14, no. 4, pp. 377–383, 2012.
- [57] N.-N. Zhang, G.-L. Huang, Q.-B. Han et al., "Functional regeneration of irradiated salivary glands with human amniotic epithelial cells transplantation," *International Journal of Clinical and Experimental Pathology*, vol. 6, no. 10, pp. 2039–2047, 2013.
- [58] M. Kawakami, H. Ishikawa, T. Tachibana, A. Tanaka, and I. Mataga, "Functional transplantation of salivary gland cells differentiated from mouse early ES cells in vitro," *Human Cell*, vol. 26, no. 2, pp. 80–90, 2013.
- [59] H. Ono, A. Obana, Y. Usami et al., "Regenerating salivary glands in the microenvironment of induced pluripotent stem cells," *BioMed Research International*, vol. 2015, Article ID 293570, 11 pages, 2015.
- [60] N. Xiao, Y. Lin, H. Cao et al., "Neurotrophic factor GDNF promotes survival of salivary stem cells," *The Journal of Clinical Investigation*, vol. 124, no. 8, pp. 3364–3377, 2014.
- [61] M. H. Aure, S. F. Konieczny, and C. E. Ovitte, "Salivary gland homeostasis is maintained through acinar cell self-duplication," *Developmental Cell*, vol. 33, no. 2, pp. 231–237, 2015.
- [62] I. M. A. Lombaert, J. F. Brunsting, P. K. Wierenga, H. H. Kampinga, G. De Haan, and R. P. Coppes, "Cytokine treatment improves parenchymal and vascular damage of salivary glands after irradiation," *Clinical Cancer Research*, vol. 14, no. 23, pp. 7741–7750, 2008.
- [63] Y. Sumita, Y. Liu, S. Khalili et al., "Bone marrow-derived cells rescue salivary gland function in mice with head and neck irradiation," *International Journal of Biochemistry and Cell Biology*, vol. 43, no. 1, pp. 80–87, 2011.
- [64] S. D. Tran, Y. Sumita, and S. Khalili, "Bone marrow-derived cells: a potential approach for the treatment of xerostomia," *International Journal of Biochemistry and Cell Biology*, vol. 43, no. 1, pp. 5–9, 2011.
- [65] J.-Y. Lim, T. Yi, S. Lee et al., "Establishment and characterization of mesenchymal stem cell-like clonal stem cells from mouse salivary glands," *Tissue Engineering—Part C: Methods*, vol. 21, no. 5, pp. 447–457, 2015.
- [66] J. N. Ferreira and M. P. Hoffman, "Interactions between developing nerves and salivary glands," *Organogenesis*, vol. 9, no. 3, pp. 199–205, 2013.
- [67] M. Ogawa, M. Oshima, A. Imamura et al., "Functional salivary gland regeneration by transplantation of a bioengineered organ germ," *Nature Communications*, vol. 4, article no. 2498, 2013.

- [68] H. Tseng, J. A. Gage, R. M. Raphael et al., "Assembly of a three-dimensional multitype bronchiole coculture model using magnetic levitation," *Tissue Engineering Part C: Methods*, vol. 19, no. 9, pp. 665–675, 2013.
- [69] H. Jaganathan, J. Gage, F. Leonard et al., "Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation," *Scientific Reports*, vol. 4, article 6468, 2014.
- [70] H. Tseng, J. A. Gage, T. Shen et al., "A spheroid toxicity assay using magnetic 3D bioprinting and real-time mobile device-based imaging," *Scientific Reports*, vol. 5, Article ID 13987, 2015.
- [71] H. Tseng, L. R. Balaoing, B. Grigoryan et al., "A three-dimensional co-culture model of the aortic valve using magnetic levitation," *Acta Biomaterialia*, vol. 10, no. 1, pp. 173–182, 2014.
- [72] J. S. Lee, J. D. Morrisett, and C.-H. Tung, "Detection of hydroxyapatite in calcified cardiovascular tissues," *Atherosclerosis*, vol. 224, no. 2, pp. 340–347, 2012.
- [73] A. C. Daquinag, G. R. Souza, and M. G. Kolonin, "Adipose tissue engineering in three-dimensional levitation tissue culture system based on magnetic nanoparticles," *Tissue Engineering Part C: Methods*, vol. 19, no. 5, pp. 336–344, 2013.
- [74] G. R. Souza, J. R. Molina, R. M. Raphael et al., "Three-dimensional tissue culture based on magnetic cell levitation," *Nature Nanotechnology*, vol. 5, no. 4, pp. 291–296, 2010.
- [75] S. Pradhan, C. Liu, C. Zhang, X. Jia, M. C. Farach-Carson, and R. L. Witt, "Lumen formation in three-dimensional cultures of salivary acinar cells," *Otolaryngology—Head and Neck Surgery*, vol. 142, no. 2, pp. 191–195, 2010.
- [76] H. Lin, N. Dhanani, H. Tseng et al., "Nanoparticle improved stem cell therapy for erectile dysfunction in a rat model of cavernous nerve injury," *Journal of Urology*, vol. 195, no. 3, pp. 788–795, 2016.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

